浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物应用分析
x

请在关注微信后,向客服人员索取文件

篇名: 浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物应用分析
TITLE:
摘要: 目的:了解浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物的临床应用情况。方法:回顾性分析浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物的使用数据,包括销售金额、用药频度(DDDs)、日均费用(DDC)等。结果:浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物的销售金额由2 530 192.33元增长至6 201 691.54元,在药品总销售金额中的占比由13.93%上升至17.40%,均呈上升趋势。阿那曲唑的销售金额各年度均排名首位。他莫西芬、阿那曲唑和来曲唑的DDDs各年度均排名前3位。DDC各年度排名首位的是戈舍瑞林。结论:浙江省11家医院2010-2015年乳腺癌患者内分泌治疗药物处方量及销售金额都呈逐年增长趋势;安全有效、经济方便的药物在临床使用中占优势。
ABSTRACT: OBJECTIVE: To investigate the status quo and tendency of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015. METHODS: The prescriptions of breast cancer patients in 11 hospitals of Zhejiang province were analyzed retrospectively in respects of consumption sum, DDDs, DDC, etc. RESULTS: The consumption sum of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015 increased from 2 530 192.33 yuan to 6 201 691.54 yuan, and its proportion in total consumption sum increased from 13.93% to 17.40%, showing increasing tendency. The anastrozole always took up the first place in the list of consumption sum. Tamoxifen, anastrozole and letrozole took up the top 3 places in the list of DDDs. Goserelin took up the first place in the list of DDC. CONCLUSIONS: The prescription amount and consumptionsum of endocrine therapy drugs in breast cancer patients from 11 hospitals of Zhejiang province during 2010-2015 show year-on-year growth trend; and those drugs which are safe, effective, economical and convenient predominate in clinic.
期刊: 2017年第28卷第26期
作者: 孙娇,孔思思,郑小卫,张轶雯,方罗
AUTHORS: SUN Jiao,KONG Sisi,ZHENG Xiaowei,ZHANG Yiwen,FANG Luo
关键字: 内分泌治疗药物;乳腺癌;销售金额;用药频度;日均费用;用药分析
KEYWORDS: Endocrine therapy drugs; Breast cancer; Consumption sum; DDDs; DDC; Analysis of drug use
总下载数: 4 次
本日下载数: 0次
本月下载数: 0次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!